Louisiana State University

LSU Digital Commons
LSU Master's Theses

Graduate School

October 2019

Evaluating Feline Release Criteria Following Iodine-131 Therapy
For Hyperthyroidism
Anthony Davila
Louisiana State University and Agricultural and Mechanical College

Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_theses
Part of the Health and Medical Physics Commons

Recommended Citation
Davila, Anthony, "Evaluating Feline Release Criteria Following Iodine-131 Therapy For Hyperthyroidism"
(2019). LSU Master's Theses. 5009.
https://digitalcommons.lsu.edu/gradschool_theses/5009

This Thesis is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has
been accepted for inclusion in LSU Master's Theses by an authorized graduate school editor of LSU Digital
Commons. For more information, please contact gradetd@lsu.edu.

EVALUATING FELINE RELEASE CRITERIA FOLLOWING IODINE-131
THERAPY FOR HYPERTHYROIDISM

A Thesis
Submitted to the Graduate Faculty of the
Louisiana State University and
Agricultural and Mechanical College
in partial fulfillment of the
requirements for the degree of
Master of Science
in
The Department of Physics and Astronomy

by
Anthony Ramon Davila
B.S., B.S., B.I.S., Louisiana State University, 2017
December 2019

This work is dedicated to my wife and my parents,
who have always supported me and believed in me.

ii

ACKNOWLEDGEMENTS
I would first like to thank Dr. Wei-Hsung Wang, my graduate advisor and committee
chair, not only for inspiring me to pursue health physics as a path of study but also for
providing me with the support I needed to conduct my own research for the first time.
Next, I would like to thank Dr. Jon Fletcher for his expertise in veterinary medicine
and his willingness to work with me on this research. His care for his patients and his
passion for research are both admirable and infectious.
Of course, I would also like to thank the rest of my committee: Dr. Kenneth
Matthews (co-chair) and Dr. Shane Stadler. They both provided valuable scientific insight
that I would not have gathered on my own. Additionally, Dr. Matthews’ radiation detection
course is the reason I first become interested in medical and health physics.
I would be remiss to not also thank my peers from the Radiation Safety Office: Dr.
Charles Wilson IV, Amin Hamideh, Jabari Robinson, and Daniel DiMarco who contributed
constructive criticisms and aided in refining my thoughts.
Lastly, I would like to especially thank my wife Lexi, who always inspires and
encourages me, and my parents Ruth and Francisco, who have always nurtured my love of
math and science.
Without each and every one of these individuals, this endeavor would not have been
possible.

This work was supported in part by a graduate fellowship from the Nuclear Regulatory
Commission.

iii

TABLE OF CONTENTS
ACKNOWLEDGEMENTS...……………………………………………………………………………………………….iii
ABSTRACT...……………………………………………………………………………………………………………………v
CHAPTER 1. INTRODUCTION.………………………………………………………………………………………….1
1.1. Iodine-131, Hyperthyroidism, and Radioactive Iodine Therapy.……………………....1
1.2. Iodine-131 Release Criteria.…………………………………………………………………………...3
1.3. Motivation and Aims.…………………………………………………………………………………......4
1.4. Conservative Assumptions in NRC Default Equation.……………………………………….6
CHAPTER 2. MATERIALS AND METHODS………………………………………………………………………...8
2.1. Radioactive Iodine Treatment at Louisiana Veterinary Teaching Hospital………...8
2.2. Administered Activities and Exposure Rates…………………………………………………11
2.3. TEDE Estimates……………………………………………………………………………………………13
2.4. Excreted Activities……………………………………………………………………………………….15
2.5. Surface Contamination…………………………………………………………………………………16
2.6. Counter Efficiencies……………………………………………………………………………………..17
CHAPTER 3. RESULTS AND DISCUSSION………………………………………………………………………..19
3.1. Injected Activities and Exposure Rates………………………………………………………….19
3.2. TEDE Estimates……………………………………………………………………………………………21
3.3. Excreted Activities……………………………………………………………………………………….26
3.4. Surface Contamination…………………………………………………………………………………28
3.5. Counter Efficiencies……………………………………………………………………………………..31
CHAPTER 4. CONCLUSIONS…………………………………………………………………………………………..33
4.1. Key Findings………………………………………………………………………………………………..33
4.2. Limitations…………………………………………………………………………………………………..34
4.3. Future Work………………………………………………………………………………………………..35
REFERENCES………………………………………………………………………………………………………………..37
VITA…………………………………………………………………………………………………………………………….41

iv

ABSTRACT
Hyperthyroidism is a very common endocrine disorder in both humans and cats.
Radioactive iodine ablation therapy is considered the gold standard; however, the patient
becomes a radiation source and poses a potential radiological risk to others. The
regulations governing when the patient can be released differ between human medicine
and veterinary medicine. A human patient can receive up to 33 mCi of I-131 and be
discharged the same day; yet a feline patient can receive a dose as low as 2 mCi and require
multiple days of hospitalization. This discrepancy has not been satisfactorily addressed;
and overly restrictive release criteria can place a burden on the veterinary staff, the patient,
and the pet owner. In this study, administered activities and exposure rates are measured
for hyperthyroid cats undergoing treatment at Louisiana State University Veterinary
Teaching Hospital to determine if current criteria are too restrictive for releasing cats to
their owners. Additionally, radioassays are performed on the surface of the cat, its excreta,
and its environment to characterize the potential exposures to the pet owners. Annual total
effective dose equivalents for the pet owners are calculated using the NRC’s equation from
NUREG-1556 Vol 9. The results of the assays show that minimal radioactivity is present.
The results of the TEDE estimates indicate that the majority of cats can be released the
same day of injection and that the resulting TEDE to the pet owner is unlikely to exceed
100 mrem, suggesting that current release criteria are overly conservative.
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CHAPTER 1. INTRODUCTION
1.1. Iodine-131, Hyperthyroidism, and Radioactive Iodine Therapy
Iodine-131 (I-131) is a radioisotope of iodine with a physical half-life of 8.02 days;
its primary decay emissions include a 606 keV β- particle with 89.6% abundance and a 364
keV γ-ray with 81.5% abundance (Knolls Atomic Power Lab 2010). I-131 is normally a
health concern after the release of fission products during a nuclear accident, as most
recently following the Fukushima Daiichi incident (Tokonami et al., 2012). I-131 emits
energetic γ-rays that pose an external exposure hazard while the β- particles can cause
internal exposures if inhaled or ingested. I-131’s preferential uptake in the thyroid along
with its biological half-life of 80 days in humans can irradiate the thyroid cells and
potentially lead to thyroid cancer. However, the same properties that make I-131 a health
concern also make it a valuable medical treatment. Any form of iodine that enters the body
subsequently enters the blood stream as iodide. Once in the blood, iodide is actively
transported from the blood into the thyroid’s functional unit, the follicle (Leggett, 2010).
The iodide is concentrated into the follicle’s lumen where it is oxidized into iodine and
incorporated into the protein thyroglobulin. Iodinated thyroglobulin is then moved back
into the follicle cell and broken down into the thyroid hormones thyroxine (T4) and
triiodothyronine (T3). After the thyroid hormones are secreted and broken down, iodine is
eventually eliminated through the kidneys and urine, primarily, but also through saliva,
feces, and sweat to a lesser extent. Medical professionals can use iodine’s biological role to
treat thyroid disorders, most commonly hyperthyroidism.
Hyperthyroidism is an common endocrinopathy characterized by an overactive
thyroid and excessive production of T3 and T4 hormones (Ross, 2011). Hyperthyroidism,
1

however, is not exclusive to humans and also afflicts cats. In fact, hyperthyroidism is the
most commonly diagnosed endocrinopathy in older felines (Peterson, 2006). While the
underlying cause of feline hyperthyroidism is not definitively known, benign, adenomatous
hyperplasia—an increased reproduction rate of non-cancerous thyroid cells—is the most
common diagnosis (Peterson, 2012). The clinical signs for a cat with hyperthyroidism most
commonly include weight-loss, increased appetite, and increased drinking and urination
due to the role that the T3 and T4 hormones play in metabolism (Peterson et al., 2016).
The therapeutic options for feline hyperthyroidism are antithyroid medications,
thyroidectomy, radioactive iodine ablation (RIA) treatment, and dietary therapy.
Antithyroid medications require multiple daily administrations which can be difficult to do
with feline patients. Even if the pill can be administered, some cats may not tolerate the
side effects associated with the medication (Peterson, 2006). Most importantly, antithyroid
medications are not curative. Dietary therapy is also non-curative, and the cat must
maintain a strict iodine-deficient diet. Dietary therapy can also be difficult due to the
dependence on the palatability of the low iodine food by the patient. Thyroidectomies, on
the other hand, are a curative treatment option when successful. However, thyroidectomy
carries the risks and complications associated with surgery and anesthesia (Peterson,
2006). Though they can be curative, thyroidectomies can also result in failure to remove all
the hyperplastic tissue resulting in relapse.
Out of the available treatment options, RIA therapy is considered the treatment of
choice by veterinarians (Carney et al., 2016). RIA is an effective and curative treatment for
feline hyperthyroidism with a majority (≥95%) of cases resolved with a single dose; RIA is
considered safe with minimal side effects and no associated mortality (Carney et al., 2016).
2

RIA’s efficacy is due to I-131’s physical and biological characteristics. The hyperplastic
thyroid tissue is hyperfunctional; therefore, the radioactive iodine becomes concentrated
there. The β- particles deposit their energy locally resulting in the ablation of those
hyperplastic tissues while sparing healthy nearby tissues (Carney et al., 2016). RIA has a
high cost up front, but the biggest disadvantage to RIA is the mandatory hospitalization
period following treatment which can last from 3 days to 4 weeks depending on the
administered dose and the regional regulations (Carney et al., 2016; Peterson, 2006). This
disadvantage to RIA is unique to treatment of feline hyperthyroidism and is not present in
treating human hyperthyroidism.
1.2. Iodine-131 Release Criteria
In human medicine, the patient release criteria for I-131 treatments are regulated
by 10 CFR 35.75 which establishes an annual total effective dose equivalent (TEDE) limit of
500 mrem to any individual and a 100 mrem limit above which instructions to maintain
doses to others as low as reasonably achievable (ALARA) are required to be provided to the
patient (CFR 2019b). NUREG-1556 Vol. 9 Rev. 2 provides guidance to medical use license
holders including an equation to calculate TEDE and tables with activities and dose rates
that are compliant with the 500 mrem and 100 mrem limits (NRC 2008). Table 1.1.
summarizes the default release criteria for I-131. If a patient is administered an activity of
33 mCi or less, hospitalization is not required. If a patient is administered an activity
greater than 7 mCi, the patient must be given radiation safety instructions. Alternatively, if
the patient has a measured dose rate less than 7 mrem/hr hospitalization is not required;
and instructions must be given for measured dose rates above 2 mrem/hr.
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Table 1.1. Summary of default release criteria for I-131
TEDE Limit Activity Dose Rate
[mrem]
[mCi]
[mrem/hr]
500
33
7
100
7
2
Adapted from NU-REG 1556 Vol 9 Rev 2
In veterinary medicine, the patient release criteria are regulated by 10 CFR 20.1301
which establishes an annual TEDE limit of 100 mrem and a limit of 2 mrem in any hour in
any unrestricted area (CFR 2019a). NCRP 148 recommends a release criterion of 0.5
mR/hr at 1 meter; however, NUREG-1556 Vol. 7 Rev. 1, which provides guidance for
academic and research license holders under which veterinary medicine falls, recommends
more restrictive release criteria (NCRP 2004, NRC 2018). Its recommendation for release
criteria is at least 4 days of hospitalization and a measured dose rate less than 0.25 mR/hr
at 1 foot (approximately 0.023 mR/hr at 1 meter) (NRC 2018). Moreover, both sets of
release criteria are factors more conservative than the 100 mrem release criteria (2
mrem/hr) from NUREG-1556 Vol. 9. The reasoning behind using more restrictive release
criteria has not been elucidated by the Nuclear Regulatory Commission (NRC).
Furthermore, the standard administered activity in feline RIA is 4 mCi, which is nearly half
the 7 mCi recommendation for exceeding 100mrem; and doses as low as 2 mCi have been
proven effective in treating feline hyperthyroidism; yet these doses require hospitalization
(Lucy et al., 2017). Meanwhile, doses used in treating human hyperthyroidism can range
from 5 mCi to 30 mCi and require no hospitalization. (Ross, 2011; Sisson et al., 2011).
1.3. Motivation and Aims
The discrepancy between the release criteria can lead to confusing interpretations
of the radiation risk. For example, this difference suggests that a cat administered 2 mCi
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poses a greater risk than a human administered 33 mCi. One could argue the feline patient
is not aware of its status as a radiation source and, therefore, cannot minimize exposure to
others; however, the pet owner can follow instructions to keep their annual TEDE ALARA.
NCRP Report No. 155 and Commentary No. 11 state that family members “should be
distinct from members of the public” and their TEDE limits “should not be as restrictive”
because they are willing to accept their radiation burden in exchange for psychological
benefits (NCRP 2006, NCRP 1995). In NUREG 1492, a regulatory analysis of patient release
criteria, the NRC acknowledges not only the economic costs to the hospital and patient
from restrictive release criteria but also the psychological benefits to the patient from less
restrictive criteria (NRC 1997). Pet owners are likely to face similar costs and benefits. A
recent survey found that the biggest concern for most pet owners when considering RIA
therapy for their cat was the hospitalization length—followed by travel distance and
financial cost (Boland et al., 2014). This same survey revealed that 82% of owners thought
their cat would be unhappy during its hospitalization and 65% of owners would miss their
cat (Boland et al., 2014). An important initial step in analyzing the costs and benefits of
different release criteria for feline patients and their owners is the assessment of dose to
the pet owner.
The aim of this current study is to provide conservative TEDE estimates of the pet
owner following their cat’s RIA therapy and characterize the potential exposures from the
cat. A multitude of studies have already investigated the dose estimates to family members
and members of the public, and they have been summarized in the Oak Ridge National Lab
(ORNL) report pertaining to patient release (Dewji and Hertel, 2017). The report’s
summary can be put simply: high doses or thyroid uptakes are typically associated with
5

failure to adhere to ALARA guidance. Additionally, numerous studies have been conducted
to provide more accurate equations that use less assumptions and more patient-specific
data or more realistic models (DeSantis and Chabot, 2001; Siegel et al., 2007; Willegaignon
et al., 2007; Zanzonico et al., 2000). These equations typically provide less restrictive
release criteria compared to the default values from NUREG-1556 Vol. 9. To provide
conservative TEDE estimates, administered activities and exposure rates of feline patients
were taken, along with other measurements to further characterize the radioactivity of the
feline patient. Then, those measurements were used with an adapted version of the NRC’s
default equation in NUREG-1556 Vol. 9 to calculate the TEDE to the pet owner. The decision
to use the default equation was based on a few reasons. First, while a couple of studies have
developed biokinetic models for I-131 in hyperthyroid cats, agreed upon values for uptake
fractions and effective half-lives for thyroidal and extrathyroidal compartments that could
be used in patient-specific models are not currently available for felines (Chen et al., 2018;
Hays et al., 1988). Second, the NRC should theoretically accept these TEDE estimates as
showing compliance with the regulations because they were derived using their own
equation. Third, the NRC default equation contains various conservative assumptions;
therefore, actual TEDEs should be lower than the estimated TEDEs if the assumptions hold.
1.4. Conservative Assumptions in NRC Default Equation
The following assumptions that are found within the NRC’s equation allow for
conservative estimates for the TEDE. The equation assumes the maximally exposed person
receives the dose from total decay. The equation contains an implicit assumption that 1
roentgen of exposure results in 1 mrem of TEDE. The equation uses the radiological halflife of I-131 and does not consider any voiding or biological elimination. Lastly, the
6

equation assumes the radioactivity of the patient is an unattenuated point source. Various
studies have demonstrated that the point source model overestimates dose from nuclear
medicine therapy patients (de Carvalho et al., 2011; Siegel et al., 2002; Sparks et al., 1998;
Yi et al., 2013).

7

CHAPTER 2. MATERIALS AND METHODS
2.1. Radioactive Iodine Treatment at Louisiana Veterinary Teaching Hospital
All data was collected in accordance with Louisiana State University (LSU)
Institutional Animal Care and Use Committee protocol #19-012. Data was collected using
feline patients at the LSU Veterinary Teaching Hospital (LSUVTH) that underwent the I-131
ablation procedure. To be included in this study, the cat must have had a diagnosis of
hyperthyroidism. Additionally the following exclusion criteria were used to limit the
factors affecting the patients’ iodine biokinetics: the cat could not have had a
thyroidectomy, could not have had advance kidney disease, could not have been
administered thyroid suppressing medication in the week prior to RIA treatment, and
could not have had thyroid cancer.
After the pet owner has decided on RIA treatment, the cat is typically admitted to
the LSUVTH on a Monday. The cat is housed inside a 70cm x 70cm x 70cm kennel in the
iodine quarantine room for the entire duration of its stay. During its hospitalization, the cat
is checked on twice daily and provided with fresh water and food and clean litter. Figure
2.1. shows a typical kennel set up.
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Figure 2.1. Typical kennel set up for feline patient receiving RIA therapy. The cat is provided
food water, and litter in a small tray. Additionally, the bottom of the kennel is lined with
towels and absorbent urine pads.
The procedure routinely takes three days followed by two days of hospitalization.
On Monday, the cat undergoes a physical exam that involves palpation of the thyroid gland
to identify the presence of any cervical mass and to assess the symmetry of the disorder.
The next day, Tuesday, a technetium-99m (Tc-99m) scan is performed to confirm the
diagnosis and aid in determining the dose of I-131. On Wednesday, the cat is administered
the sodium iodide I-131 solution via intrascapular subcutaneous injection, see Figure 2.2.
LSUVTH utilizes low dose RIA and typically prescribes doses ranging from 2 mCi to 3 mCi.
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Figure 2.2. A cat receiving an intrascapular subcutaneous injection.
Source: https://vcahospitals.com/know-your-pet/giving-injections-to-cats

Following injection, a radiation survey of the room is performed in order to identify
any potential contamination. The feline patient typically remains in quarantine until Friday
when a survey of the cat is performed to determine if the 0.5 mR/hr at 1 m release criteria
used by LSUVTH is satisfied. If the feline patient’s exposure rate is below the criteria, the
cat is released back into owner custody that afternoon. If the exposure rate does not meet
the criteria, the patient remains hospitalized until the reading falls below the criteria so
that the cat can be safely released back to the owner. After the cat is released, the owner
must follow radiation safety instructions to minimize their exposure. Figure 2.3. shows the
instructions provided to pet owners.
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Figure 2.3. Home care instructions given to pet owners following their cats’ RIA therapy.
These instructions help keep the dose to the pet owner ALARA.
2.2. Administered Activities and Exposure Rates
In this study, seven feline patient case studies were followed that spanned from
February to May of 2019. One cat was subsequently removed from the study because a
review of its medical history revealed that a thyroidectomy had been previously
performed. Administered activities were calculated by measuring the syringe’s activity
before and after patient injection using
𝑄 = 𝐴𝑓 − 𝐴0

(Equation 2.1)

where Q is the administered activity in mCi, Af is the activity in the syringe after injection,
and A0 is the activity in the syringe before injection. The 108 cm exposure rate readings in
mR/hr were taken immediately after injection (day 0) and repeated each subsequent day
(day 1 and day 2) during their hospitalization using a Fluke 451B ion chamber survey
meter with a closed beta slide, pictured in Figure 2.4. Feline patients were discharged on
11

day 2 in accordance with the regular veterinary practice if they met the release criteria and
were not kept hospitalized for the purposes of this study as that would not be considered
ethical.

Figure 2.4. Fluke 451B ion chamber survey meter used to perform exposure rate
measurements in units of mR/hr.
To consistently perform the survey readings and reduce variability from distance,
the cats were placed in a pet carrier to limit their movements. Tape was used to mark the
100±1cm distance from the front of the carrier. However, the cat thyroid was maximally
located 8±2cm into the carrier from the front. Therefore, exposure rate readings were
taken at 108±2cm. Exposure rates at one meter were then calculated using the inverse
square law
𝑑2

𝑋1 = 𝑋0 𝑑02

(Equation 2.2.)

1

where X1 is the exposure rate at one meter, X0 is the measured exposure rate at 108 cm, d02
is the distance of the measured exposure rate, 108 cm, and d 12 is 100 cm. The inverse
12

square law was also used to calculate the distance at which the exposure rate increases to 2
mR/hr
𝑑2 = √

𝑋1𝑑12
𝑋2

(Equation 2.3.)

where d2 is the distance at which the exposure rate increases to 2 mR/hr, d 1 is 100cm in
distance, X1 is the one-meter exposure rate, and X2 is an exposure rate of 2 mR/hr. Figure
2.5. shows this experimental set-up. Additionally, five readings were taken at each survey.
The mean exposure rate measurements were then fitted to an exponential curve to obtain
an effective half-life of I-131 for each patient.

Figure 2.5. Experimental set-up for collection of exposure rate data. The distance between
the blue tape is 100 ± 1 cm.
2.3. TEDE Estimates
TEDE estimates were calculated using administered activities and the exposure
rates for each of the three days during the patient’s hospitalization. The TEDE to the pet
owner from each cat was calculated using an equation adapted from equation U.2. in
NUREG-1556 Vol. 9 Rev. 2
13

𝑇𝐸𝐷𝐸(∞) =

34.6Γ𝑄𝑇𝑃 𝐸
𝑟2

(Equation 2.4.)

where TEDE is the estimated total effective dose equivalent in mrem from total decay, 34.6
is the product of the 24hr/d conversion factor and the total integration of decay (1.44), Γ is
𝑚𝑅∙𝑚 2

0.22 ℎ𝑟∙𝑚𝐶𝑖 the specific gamma constant for I-131, Q is the administered activity in mCi, Tp is
the physical half-life of 8.02 days, E is the occupancy factor, r is the distance in meters
(2008). The TEDE was calculated using both the administered activities and the exposure
rate measurements and using occupancy factors of both 0.25 and 1. NUREG 1556 Vol 9 uses
an occupancy factor of 0.25 for radionuclides with half-lives greater than 1 day. In this
study, an occupancy factor of 1 was also used to simulate a situation where the pet owner
could feasibly be at home all day with the cat such as a retiree or someone who works from
home. When calculating TEDE from exposure rates, the product ΓQ is replaced by the 1m
exposure rates, X1.
𝑇𝐸𝐷𝐸(∞) =

34.6𝑋1 𝑇𝑃 𝐸
𝑟2

(Equation 2.5.)

Implicit in both Equation 2.4. and Equation 2.5. is a 1 R=1 rem conversion factor. The
committed effective dose equivalent estimates for the inhalation and ingestion pathways
were calculated using equation B.3. from NUREG-1556 Vol. 9 Rev. 2.
𝐶𝐸𝐷𝐸 = 𝑄 ∗ 10−5 ∗ 𝐷𝐶𝐹 ∗ 1000

(Equation 2.6.)

where CEDE is the committed effective dose equivalent in mrem, Q is the administered
activity in mCi, 10-5 is the NRC’s assumed fractional intake, DCF is the I-131 dose
conversion factor from the EPA Federal Guidance Report No 11 for either inhalation or
ingestion in rem/mCi, 1000 is for the conversion from rem to mrem (EPA 1988).
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2.4. Excreted Activities
Urine and fecal samples were collected from the patients to measure the amount of
radioactivity excreted. Urine samples were collected in the form of either urine-soaked
litter or a urine-soaked pad. For simplicity, both forms will simply be referred to as urine
samples. The urine and fecal samples were collected at each check-in, and the excreta were
placed in rigid syringe packs for 12 mL syringes, pictured in Figure 2.6. The rigid syringe
packs were initially used so that the samples’ activities could be easily measured using a
Biodex Atomlab 100 dose calibrator, shown in Figure 2.7. However, the rigid syringe packs
limited the amount of sample that could be measured at once; so they were replaced with
16.5x14.9 cm2 sealable zipper polyethylene sandwich storage bags for later samples due to
the large amount of excreta that some patients produced. Urine pad samples were only
collected when the staff determined urine was present based on visual and tactile
inspection. The contaminated portion of the pad was removed with scissors to then be
measured in the dose calibrator. Excreta samples were measured three times, and samples
were grouped into 24-hour bins starting from time of injection. The excreta samples were
decay corrected to the time of injection and used to calculate the ratio of the excreted
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activity to the injected activity and multiplied by 100 to obtain the percent excreted
activity.

(a)

(b)

Figure 2.6. Containers used to measure the activity of the excreta in the dose calibrator (a)
Rigid syringe pack for a 12 mL syringe (b) Sealable zippered polyethylene sandwich
storage bag

Figure 2.7. Biodex Atomlab 100 dose calibrator used to measure excreted activity.
2.5. Surface Contamination
Wipe tests were performed on the feline patients to detect any removable
contamination on the cats’ surfaces. A wipe test was performed on each patient before
16

injection and repeated once each day during its hospitalization. The methodology for the
wipe tests was adapted from Chalmers et al, 2006. One wipe was used to survey from the
dorsal midline at the base of the neck extending caudally to the base of the tail as well as
laterally along the abdomen areas. Another wipe was used to survey all the paws on both
the dorsal and palmar/plantar surfaces. The wipes used were 1 in2 polystyrene wipes. The
wipes were then measured using one-minute counting times in a Packard Cobra II Model
5002 gamma counter (Figure 2.8.a) and, subsequently, in a Beckman Model LS 6000LL
liquid scintillation counter (LSC) (Figure 2.8.b). The net count rates were then converted to
activity using each detectors’ efficiency. Additionally, wipe tests were performed on the
kennel interior, food bowl, and water bowl at the time of patient discharge. The wipe of the
kennel interior covered the lower half of the three kennel walls along with the kennel floor.

(a)

(b)

Figure 2.8. (a) Packard Cobra II Model 5002 gamma counter used to detect the gamma
activity present on the wipes. (b) Beckman Model LS 6000LL liquid scintillation counter
used to detect activity from beta-minus radiation on the wipes.
2.6. Counter Efficiencies
To determine the efficiency of the gamma counter and LSC, six samples were
prepared with a known radioactivity of iodine-131. A sodium iodide I-131 solution of 4
mCi/ml obtained by Cardinal Health was serially diluted to 0.1 µCi/µL. Two microliter
17

drops were added to six polystyrene wipes, resulting in an activity of 0.2 µCi on each wipe.
Three wipes were used to determine the efficiency of the gamma counter, and three were
used to determine the efficiency of the LSC. The samples’ count rates were measured using
five-minute counting times at weekly intervals for 8 weeks. The measured count rates of
the three samples were averaged and then divided by the expected disintegrations per
minute, calculated using the known activity, to determine the counter’s efficiency.
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CHAPTER 3. RESULTS AND DISCUSSION
3.1. Injected Activities and Exposure Rates
The cats were treated with activities of carrier free sodium iodide I-131 in the range
of 1.62 to 2.54 mCi with an average administered activity of 2.14 mCi. Mean exposure rates
at 1 meter ranged from 0.23 to 0.46 mR/hr on day 0, from 0.19 to 0.43 mR/hr on day 1, and
from 0.13 to 0.38 mR/hr on day 2. The values of the administered activities and the mean
exposure rates are tabulated in Table 3.1. All administered activities were well below the
NRC’s calculated activity limit for exceeding 100 mrem TEDE of 7 mCi. Additionally, all
mean exposure rates are well below the corresponding dose rate limit of 2 mrem/hr. These
findings suggest that the TEDE to the pet owner should be well below 100 mrem if an
occupancy factor of 0.25 at a distance of 100 cm are valid assumptions.
Table 3.1. Administered activities and mean exposure rates at 1 meter.
Exposure Rate [mR/hr]
Cat
Prescribed Activity
Administered
Day 0
Day 1
Day 2
[mCi]
Activity [mCi]
1
2.25
1.79±0.06
0.24±0.02 0.20±0.02 0.14±0.01
2
2.94
2.48±0.08
0.47±0.02 0.43±0.01 0.34±0.01
3
2.25
1.62±0.05
0.28±0.04 0.22±0.01 0.21±0.01
4
2.50
1.92±0.06
0.23±0.02 0.19±0.01 0.13±0.01
5
3.00
2.46±0.08
0.43±0.02 0.41±0.01 0.38±0.01
6
3.00
2.54±0.08
0.36±0.02 0.38±0.01 0.30±0.01
The administered activity values are the difference in the measured activity of the syringe
before and after patient injection. The exposure rate values are the calculated exposure
rates for 1 meter based on the measured exposure rates at 108 cm. Values are reported as
the mean value plus/minus their standard error.
The distances at which the exposure rate increases to 2 mR/hr ranged from 0.34 to
0.48m on day 0, 0.31 to 0.46m on day 1, and 0.25 to 0.44m on day 2. Instructions should be
given to the pet owner warning against spending an appreciable amount of time at this
distance or closer to the cat. These distances can be found in Table 3.2. Based on these
19

results, if a pet owner maintains a distance of at least half a meter, then they should likely
not receive more than 2 mrem in any hour.
Table 3.2. Distance[m] at which the exposure rate increases to 2mR/hr.
2 mR/hr distance [m]
Cat
Day 0
Day 1
Day 2
1 0.35±0.02 0.31±0.02 0.26±0.01
2 0.48±0.01 0.46±0.01 0.41±0.01
3 0.37±0.02 0.33±0.01 0.32±0.01
4 0.34±0.02 0.31±0.01 0.25±0.01
5 0.46±0.01 0.45±0.01 0.44±0.01
6 0.43±0.01 0.44±0.01 0.39±0.01
Values are reported as the expected value plus/minus its standard error. A pet owner
standing this distance from their pet for 1 hour would be exposed to 2 mR.
Figure 3.1. illustrates exposure rates over time. The exposure rates were fitted to an
exponential curve to determine the effective half-life and, subsequently, to calculate the
biological half-life. Effective half-lives ranged from 2.2 to 14 d and biological half-lives from
-19 to 72 d. Those values are tabulated in Table 3.3. Cats 1, 2, and 4 have R2 values over
0.90 indicating that the variation in the data is explained by an exponential model.
Additionally, the effective half-lives of cats 1, 2, and 4 are in agreement with the current
literature ranging from 2 to 4 days (Martin et al., 2015; Roberts et al., 2015). This
agreement suggests that cats 1, 2, and 4 exhibit the expected feline biokinetics for iodine131. Meanwhile, cats 3, 5, and 6 have unexpected biokinetics for iodine. Cat 5 had a high R2
value, however, its effective half-life of 14 days is longer than expected. Similarly, cats 3 and
6 have longer than expected half-lives of 4.8 and 7.2 days, respectively. Cat 6’s low R2 value
can be explained by its exposure rate increase from 0.36mR/hr on day 0 to 0.38 mR/hr on
day 1, suggesting that cat 6 exhibits slow uptake. Effective half-lives less than or equal to 4
days are ideal as that signifies the feline patient is eliminating the I-131 faster than the I131 decays, which would reduce the pet owners’ exposure when in the vicinity of the cat.
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Feline Exposure Rates at 1 m vs Time
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Figure 3.1. Semi-log plot of patients’ exposure rates at 1 meter over time. The exposure
rates were fitted to an exponential curve. Error bars signify plus/minus standard error.
Table 3.3. Effective half-lives and biological half-lives
Cat
TE [d]
R2
TB [d]
1
2.2
0.99
3.0
2
3.6
0.95
6.5
3
4.8
0.85
12
4
2.1
0.99
2.8
5
14
0.99
-19
6
7.2
0.51
72
Effective half-lives (TE) are listed in the second column with their respective coefficient of
determination (R2) in the third column. The last column contains the biological half-lives
(TB) calculated from the effective half-lives.
3.2. TEDE Estimates
The calculated TEDEs based on administered activity are tabulated in Table 3.4.,
while TEDEs based on measured exposure rates are tabulated in Table 3.5. The TEDE
estimates using administered activity ranged from 25 to 39 mrem and from 99 to 155
mrem, for occupancy factors of 0.25 and 1, respectively. These estimates are also
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represented graphically in Figure 3.2. As illustrated in Figure 3.2., the estimated TEDEs
based on administered activity and an occupancy factor of 0.25 are well below the 100
mrem limit. Based on these results, all feline patients could have been released the day of
injection without exceeding the pet owner’s annual limit. This result is expected given that
all the administered activities are less than the NRC’s limit of 7 mCi. In the case of an
occupancy factor of 1, for pet owners who are able to stay home with their cat all day, the
estimated TEDEs for all but cat 3 exceed the 100 mrem. Only cat 3 could have been released
the day of injection. Equation 2.4. can be solved empirically for the administered activity.
Using an occupancy factor of 1 and TEDE limit of 100 mrem, administered activities would
have to be below 1.64 mCi to release the patient the same day as injection. While low doses
have been demonstrated to successfully treat feline hyperthyroidism by Lucy et al, this
restrictive activity criteria can be circumvented by using measured dose rates as the
release criteria (Lucy et al., 2017).
Table 3.4. TEDE estimates based on administered activity
TEDE [mrem]
Cat Injected Activity [mCi] E = 0.25
E=1
1
1.79±0.06
27±1
109±4
2
2.48±0.08
38±1
152±5
3
1.62±0.05
25±1
99±3
4
1.92±0.06
29±1
117±4
5
2.46±0.08
38±1
150±5
6
2.54±0.08
39±1
155±5
Values are reported as expected value plus/minus standard error.
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Figure 3.2. TEDE estimates based on administered activity. Error bars indicate plus/minus
one standard error.
The TEDE estimates using exposure rates and 0.25 occupancy ranged from 16 to 32
mrem, 13 to 30 mrem, and 9 to 27 mrem for days 0, 1 and 2, respectively, and are
illustrated in Figure 3.3.a. Again, the TEDE estimates using an occupancy factor of 0.25 are
well below the 100 mrem limit. This result is expected since all the measured exposure
rates are below the NRC’s limit of 2 mrem/hr, again suggesting that all feline patients could
have been released on day 0 without exceeding the pet owner’s annual limit. The TEDE
estimates using exposure rates and an occupancy factor of 1 ranged from 65 to 130 mrem,
52 to 120 mrem, and 36 to 107 mrem, for days 0, 1, and 2, respectively. These estimates are
illustrated in Figure 3.3.b. Like Equation 2.4., Equation 2.5. can also be solved analytically.
The dose rate that corresponds to a 100 mrem limit and occupancy factor of 1 is 0.36
mrem/hr. And indeed, this is evident in the results. Four of the cats could have been
released on day 0, while cats 2 and 5 were not suitable for release until day 2. These results
show the advantage of dose-rate-based release criteria over activity-based release criteria.
While using the activity-based release criteria with an occupancy factor of 1, none of the
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cats could have been released on injection day. In contrast, the dose-rate-based criteria
could have allowed 4 out of 6 cats to be released on injection day. Further support for the
use of dose-rate-based criteria comes from a previous studies that failed to find a linear
relationship between measured exposure rates and administered activity (Feeney et al.,
2003; Weichselbaum et al., 2003). Other studies have also established that the measured
dose rate is typically less than the calculated dose rate due to patient specific parameters
such as self-shielding and biokinetics (Siegel et al., 2002; Yi et al., 2013). Therefore, using
measured dose rates for release criteria is recommended because the TEDE estimates
provided are more realistic compared to those calculated using administered activities,
while still maintaining the conservativism of the NRC’s equation.
Table 3.5. TEDE estimates based on measured exposure rates
TEDE [mrem]
Exposure Rate [mR/hr]
E = 0.25
Cat
Day 0
Day 1
Day 2
Day 0 Day 1 Day 2 Day 0
1 0.24±0.02 0.20±0.02 0.14±0.01 17±2 14±2 10±1 68±7
2 0.47±0.02 0.43±0.01 0.34±0.01 32±2 30±1 23±1 129±7
3 0.28±0.04 0.22±0.01 0.21±0.01 19±2 15±1 14±1 78±10
4 0.23±0.02 0.19±0.01 0.13±0.01 16±2 13±1 9±1
65±7
5 0.43±0.02 0.41±0.01 0.38±0.01 30±2 28±1 27±1 120±7
6 0.36±0.02 0.38±0.01 0.30±0.01 25±1 27±1 21±1 100±4
Values are reported as expected value plus/minus uncertainty.
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E=1
Day 1 Day2
55±7 39±3
120±4 94±4
61±3 58±3
52±3 36±3
113±4 107±4
107±4 84±4
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(b)
Figure 3.3. (a) TEDE estimates based on measured exposure rates using an occupancy
factor of 0.25. Error bars indicate plus/minus one standard error. (b) TEDE estimates
based on measured exposure rates using an occupancy factor of 1. Error bars indicate
plus/minus one standard error.
The CEDE estimates ranged from 0.53 to 0.84 mrem for the inhalation pathway and
0.86 to 1.35 mrem for the ingestion. CEDE estimates for each pathway and their sums are
tabulated in Table 3.6. NUREG-1556 Vol. 9. recommends neglecting CEDE if it makes up less
than 10% of the TEDE. The CEDE is 5.6% for all cats and, therefore, can be ignored. The fact
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that the CEDE was 5.6% of the TEDE for all cats is due to the fixed nature of the TEDE and
CEDE equations used. When a ratio of CEDE to TEDE is calculated, the administered activity
term Q cancels out, leaving a ratio of 0.056 which is independent of the administered
activity. Given the already low doses administered to feline patients, these findings
reinforce that the dose contribution from internal exposures is negligible especially
compared to dose contributions from external exposures.
Table 3.6. Committed Effective Dose Equivalent from inhalation and ingestion pathways
CEDE [mrem]
Cat
Administered
Inhalation Ingestion Cumulative %TEDE*
Activity [mCi]
1
1.79±0.06
0.59±0.02 0.95±0.03 1.54±0.04
5.6
2
2.48±0.08
0.82±0.03 1.32±0.04 2.14±0.05
5.6
3
1.62±0.05
0.53±0.02 0.86±0.03 1.39±0.03
5.6
4
1.92±0.06
0.63±0.02 1.02±0.03 1.65±0.04
5.6
5
2.46±0.08
0.81±0.03 1.30±0.04 2.11±0.05
5.6
6
2.54±0.08
0.84±0.03 1.35±0.04 2.19±0.05
5.6
Values are reported as the expected value plus/minus its standard error.
*%TEDE calculated as the ratio of the CEDE estimates and TEDE estimates based on
administered activities and an occupancy factor of 0.25
3.3. Excreted Activities
The percent total excreted activity for the feline patients ranged from 1.09% to
9.25% in the first 24-hours and from 2.32% to 16.54% in the second 24-hours. Table 3.7.
lists the percent excreted activity for the urine-soaked litter, urine pads, feces, the total for
each day, and the 48hr total. The total percent excreted after 48 hours ranged from 3.41%
to 24.50% which is lower than results from previous studies that found at least 50% of
activity excreted in the first 48 hours (Feeney et al., 2003; Lamb et al., 2013; Martin et al.,
2015).
This part of the experiment was not without difficulties. Excrement samples were
initially collected using rigid syringe packs (pictured in Figure 2.7.). Rigid syringe packs
26

were initially chosen because they allowed for easy measurement of the sample’s activity in
the dose calibrator. However, the rigid syringe packs were deemed inefficient due to the
restrictive sample amount that could be collected compared to the amount of excreted
material to be analyzed. Starting with cat 4, the packs were replaced with polyethylene
sandwich bags. The polyethylene sandwich bags allowed for greater amounts of excreta to
be measured within the dose calibrator. Another difficulty was the inconsistent urine and
feces production of the patients. Some patients did not produce feces within a given 24-hr
period. On some occasions, the patients spilled contaminated litter outside of the tray. On
others, patients would not contain their urine production within the litter tray although
this loss was partly mitigated by the urine pads. Although the % activity excreted was
lower than expected, % activity excreted in urine was higher than % activity excreted in
feces for any given cat in either 24-hr period. This result is expected due to the fact that
iodine clears out the body predominantly through the kidneys (Leggett, 2010).
Table 3.7. Percent activity excreted
% Activity Excreted
1st 24 hours
2nd 24 hours
Cumulative Total
Cat Litter
Pad
Feces
Total
Litter
Pad
Feces
Total
1 0.64±0.02
*
0.60±0.02 1.24±0.03 2.71±0.09
*
**
2.71±0.09
3.95±0.09
2 1.58±0.05
*
**
1.58±0.05 3.86±0.12
*
**
3.86±0.12
5.44±0.13
3 1.09±0.03
*
**
1.09±0.03 2.22±0.07
*
0.10±0.00 2.32±0.07
3.41±0.08
4 9.25±0.39
*
0.04±0.00 9.29±0.39 9.51±0.40
*
**
9.51±0.40
18.80±0.56
5 7.50±0.24 0.46±0.02
**
7.96±0.24 8.04±0.26 5.05±0.16 3.45±0.11 16.54±0.32 24.50±0.40
6 4.17±0.13
*
**
4.17±0.13 4.27±0.14
*
1.48±0.05 5.75±0.15
9.92±0.20
Values are reported as the expected value plus/minus its uncertainty.
*Urine-pad activity was measured if visual or tactile inspection indicated the presence of
urine.
** Some feline patients did not produce fecal samples throughout the 24-hour period.
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3.4. Surface Contamination
The wipe tests done before injection were all within background, but wipes from
day 1 and day 2 detected removable radioactivity on the surface of the patients. Figure 3.4.
and Figure 3.5. show the surface activity from the gamma counter measurements and LSC
measurements, respectively. Surface contamination on day 1 ranged from 0.16 to 0.52 nCi
on the body and from 0.08 to 0.80 nCi on the paws based on the gamma counter and its
efficiency. Surface contamination ranged from 0.20 to 0.46 nCi on the body and from 0.08
to 0.73 nCi on the paws based on the LSC and its efficiency. The presence of removable
contamination is expected given that iodine can be eliminated from the body through the
salivary glands. When the patient grooms themselves, they deposit the radioactive iodine
from the saliva onto their surface. However, cross-contamination from contaminated litter
could potentially contribute to the removable contamination found on the surface of the
patient, especially on the paws. Regardless of the source of the removable contamination,
our data shows that the activities are below 1 nCi. Additionally, our data shows that Day 2
activities were significantly lower than or equal to Day 1 activities, but never significantly
higher.
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Figure 3.4. Surface Activity on feline patient based on gamma counter measurements.
The blue columns indicate the surface activity of the body, while gold columns indicate
activity for the paws. Error bars indicate plus/minus one standard deviation.

Surface Contamination based on LSC
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Figure 3.5. Surface activity on feline patient based on LSC measurements. The blue columns
indicate the surface activity of the body, while gold columns indicate activity for the paws.
Error bars indicate plus/minus one standard deviation.
Aside from the cat’s surface, any surface that could become contaminated and
subsequently touched by the pet owner was of interest. Food and water bowls were
assayed as well as the kennel interior. Activities on these other surfaces are shown in
Figures 3.6. and 3.7. for the gamma counter and LSC, respectively. Activities on the kennel
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interior ranged from 0.08 nCi to 4.84 nCi based on measurements from the gamma counter
while they ranged from 0.07 nCi to 3.89 nCi based on LSC measurements. Activities on the
food bowl and water bowl ranged from 0.01 nCi to 0.20 nCi and 0.03 nCi to 0.17 nCi,
respectively, for the gamma counter. For the LS counter, activities on the food and water
bowls ranged from 0.04 nCi to 0.19 nCi and 0.03 nCi to 0.14 nCi, respectively. The food and
water bowls had negligible activities whereas the kennel interior had activities elevated
above background. However, the reason for the elevated activities is unclear and is not
present for all the patients. The little contamination present on the bowls was likely from
any saliva transfer when the patient was eating and drinking. Contamination inside the
kennel may be from the patient rubbing against the walls or floor; however, the activities
on the surface of the cat were lower than those found on the kennel interior. The elevated
activities could more likely be explained by urine contamination from improper use (or
lack of use) of the litter tray.

Contamination on other surfaces based on gamma
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Figure 3.6. Contamination on other surfaces based on gamma counter measurements. Error
bars indicate plus/minus one standard deviation.
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Contamination on other surfaces based on LSC
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Figure 3.7. Contamination on other surfaces based on LSC measurements. Error bars
indicate plus/minus one standard deviation.
3.5. Counter Efficiencies
Figures 3.8. and 3.9. show the measured count rates as a function of time along with
their efficiencies for the gamma counter and LSC, respectively. As illustrated in Figure 3.8.,
the count rates obtained with the gamma counter are well fitted to an exponential curve.
The same result is apparent in Figure 3.9. apart from the first data point. The explanation
for this deviant data point is likely that the activity was saturating the LSC resulting in
increased dead time, which would also explain why that data point has the lowest
efficiency. For the gamma counter, an efficiency of 0.3 was used when calculating activities
from the counting data. An efficiency of 0.3 was decided upon because the magnitudes of
the measured count rates of the last data point are comparable to those measured on the
surface of the patient. Following similar logic, an efficiency of 0.66 was used for
determining activities using counting data from the LSC.
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Figure 3.8. Count rates and efficiencies from gamma counter. Error bars indicate
plus/minus one standard deviation.
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Figure 3.9. Count rates and efficiencies from LSC. Error bars indicate plus/minus one
standard deviation.
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CHAPTER 4. CONCLUSIONS
4.1. Key Findings
The present study characterized several aspects of radiation exposure to the pet
owner from their cat. Half of the cats had effective half-lives consistent with the literature
of less than 4 days. Effective half-lives in this range are preferable because the radioactivity
is eliminated so the exposure to the pet owner from the cat itself is reduced. Additionally, if
the pet owner is greater than half a meter away, then the received dose should not exceed 2
mrem in any hour for cats that were administered activities no greater than 2.54 mCi.
The main elimination pathway of iodine in cats is through the urine as evidenced by
the urine samples’ containing the highest amounts of radioactivity. Radioactivity was also
found, though in smaller amounts, on the surface of the cat and its environment. This
radioactivity is suspected to come from contamination from saliva, but urine contamination
is also possible. Typically, surface contamination was present at levels below 1 nCi;
however, some exceptions were found on the surface of the inside of the cage. The
elimination pathway behind the elevated activity inside the cage is unknown but suspected
to be from urine contamination.
Aside from characterizing the sources of exposure, this study provides conservative
estimates of TEDE to the pet owner following their cats’ RIA therapy. Using the NRC’s
default equations, this study demonstrated that the CEDE is always less than 10% of the
TEDE and can be neglected. With an occupancy factor of 0.25 at a distance of 100 cm,
calculated TEDEs to the pet owners were well below the 100 mrem limit; and the feline
patients could, in theory, have been safely sent home the day of injection with home care
instructions for the owner. Even when using the more conservative occupancy factor of 1,
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the majority of the patients could have been sent home the day of injection without the pet
owners’ TEDE exceeding 100 mrem. These results coupled with the conservatism built into
the equation suggest that the actual TEDE to the pet owner is not likely to exceed 100
mrem for administered activities below 2.54 mCi assuming the pet owner does not
blatantly disregard the home care instructions.
4.2. Limitations
This study had several limitations in its design, the first being its small sample size.
A larger sample size would allow for more accurate generalizations to be drawn from the
data and would reduce the effects of any possible outliers. One result of the small sample
size is a limited administered activity range. The standard dose for treating feline
hyperthyroidism is 4 mCi; LSUVTH prescribes a maximum of 3 mCi. The highest
administered activity in the study is 2.54 mCi, meaning that our TEDE, effective half-life,
excreted activity, and surface contamination data may not be applicable for administered
activities above 2.54 mCi. In addition to small sample size, short collection time is another
limitation. Data was only collected over the two days which is short compared to the 8-day
physical half-life of I-131. Ideally, data would have been collected over a longer period of
time; but patients could not have been held past when they met the release criteria for
ethical reasons. Other limitations are the previously mentioned issues with collecting urine
and feces samples. The container used to hold the samples and measure them in the dose
calibrator was changed partway through the experiment. This change makes comparing
samples across all patients difficult without knowing the affect the containers had on the
measured activity in the dose calibrator. Additionally, some excreted activity was lost due
to poor containment within the litter pan. Lastly, cat movement during exposure rate
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measurements was a source of uncertainty. Though steps were taken to minimize this
effect, feline patients did not necessarily stay still during data collection, causing
fluctuations in the exposure rate readings.
4.3. Future Work
The conservative TEDE estimates presented here could provide the preliminary
groundwork for analyzing the costs and benefits of less restrictive release criteria for feline
patients. Another factor that should be addressed in detail are the economic costs on
veterinary hospitals and pet owners when more restrictive release criteria are used.
Moreover, the present study addresses TEDE estimates to the pet owner when they have
one cat that receives RIA therapy. However, cats have relatively short lives compared to
humans; therefore, a single pet owner can have multiple cats throughout their lifetime that
receive RIA therapy. A single pet owner can also have multiple cats at the same point in
time that require the treatment. These such circumstances should be considered in any
future cost-benefit analysis
Another aspect of feline patient release that should be addressed in depth in future
studies is managing the cat’s biological waste. The activities present in the litter at the time
of release would be high enough to set off radiation detectors at the local landfill. Pet
owners are already given instructions to hold waste for 2 weeks so that the radiation
decays away. However, no methodology has been presented to keep doses ALARA while
handling and storing the waste.
This study provides insight on the radioactive characteristics of a cat during
hospitalization; repeating these measurements on a cat that is released to its owner the
same day as injection would be interesting to see if any significant changes in the data
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occur when the cat is in its home environment. Cats during hospitalization may be less
likely to eat and drink, and therefore, less likely to urinate and defecate. Cats may not
groom themselves as much when hospitalized. Conversely, they may groom excessively.
Once at home a cat may not spend time in close contact with a contaminated litter box. All
these factors can affect how the radioactivity is excreted from the cat and affect its
potential to spread contamination.
Moreover, TEDE estimates that account for patient attenuation, source geometry,
fractional uptakes, and effective half-lives could further help illuminate whether feline
release criteria are too restrictive. Measurements of pet owner thyroid burden after the cat
has been home for some time could also provide insight into the TEDE received by pet
owners.
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